Differences in the proportions of fluoroquinolone-resistant Gram-negative bacteria isolated from bacteraemic children with cancer in two Italian centres

Clinical Microbiology and Infection

Volumn 11, Issue 6, 2005, Pages 505-507

  Castagnola, Elio ^a   Haupt, R ^a   Micozzi, A ^b   Caviglia, I ^a   Testi, A M ^b   Giona, F ^b   Parodi, S ^a   Girmenia, C ^a  

^a G GASLINI INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Cancer patients; Children; Ciprofloxacin; Fluoroquinolone resistance; Prophylaxis; Resistance

Indexed keywords

AMIKACIN; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BLOOD CULTURE; CANCER; CHILD; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION PREVENTION; ITALY; LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

NEGIBACTERIA;

EID: 19744377669     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2005.01114.x     Document Type: Article

References (15)

1. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1188.
2. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996; 23: 795-805.
3. Cometta. A, Calandra T, Bille J et al. Escherichia coli resistant to fluoroquinolone prophylaxis in patients with cancer and neutropenia. N Engl J Med 1994; 330: 1240-1241.
4. Kern WV, Andriof E, Oethinger M et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38 681-687.
5. Caratalla J, Fernandez-Sevilla A, Dominguez MA et al. Emergence of fluoroquinolone-resistant flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503-505.
6. Zervos MJ, Hershberger E, Nicolau DP et al. Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones in selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis 2003; 37: 1643-1648.
7. Richard P, Delangle MH, Merrien D et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994; 19: 54-59.
8. Lautenbach E, Fishman NO, Bilker WB et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med 2002; 25: 2469-2477.
9. American Academy of Pediatrics. Antimicrobial agents and related therapy: fluoroquinolones. The red book on CD-ROM - report of the Committee on Infectious Diseases, 26th edn. Elk Grove Village, IL: American Academy of Pediatrics, 2003.
10. Mullen CA. Ciprofloxacin in treatment of fever and neutropenia in pediatric cancer patients. Pediatr Infect Dis J 2003; 22: 1138-1142.
11. Viscoli C, Castagnola E. Treatment of febrile neutropenia: what is new? Curr Opin Infect Dis 2002; 15: 377-382.
12. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Ann Intern Med 1991; 115: 7-12.
13. Viscoli C, Castagnola E, Caniglia M et al. Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology 1998; 55: 489-500.
14. Jorgensen JH, Turnidge JD, Washington JA. Antibacterial susceptibility tests: dilution and disk diffusion methods. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of clinical microbiology. Washington, DC: American Society for Microbiology Press, 1999; 1526-1543.
15. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley, 2000.